ReviewOncoTargets and therapy2016
Esophageal cancer stem cells and implications for future therapeutics.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Surface Markers for the Identification of Cancer Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Prediction of recurrence free survival for esophageal cancer patients using a protein signature based risk model.Oncotarget · 2022Article
- Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.Journal of oncology · 2022Review
- The tumour immune microenvironment in oesophageal cancer.British journal of cancer · 2021Review
- Chemoprotective Effect of Daphnetin in Doxorubicin Treated Esophageal Cancer Stem Cell Xenograft Tumor Mouse.Doklady. Biochemistry and biophysics · 2021Article
- Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.Molecular cancer · 2021Review
- Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-BioMed research international · 2021Article
- Gastrointestinal cancer stem cells as targets for innovative immunotherapy.World journal of gastroenterology · 2020Review
- GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Primary impact of Gli1 on radioresistance in esophageal cancer.Oncology letters · 2019Article
- Article
- High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis.Medicine · 2019Article
- Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications.Journal of hematology & oncology · 2018Review
- Article
- DSPP-MMP20 gene silencing downregulates cancer stem cell markers in human oral cancer cells.Cellular & molecular biology letters · 2018Article
- Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.Carcinogenesis · 2017Article
- Analysis of risk factors for post-operative complications and prognostic predictors of disease recurrence following definitive treatment of patients with esophageal cancer from two medical centers in Northwest China.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma (EC) is a lethal disease with high morbidity and mortality worldwide, and the incidence has been increasing in recent years. Although the diagnosis and treatment of EC have improved considerably, EC has rapidly progressed in the clinical setting and has a poor prognosis for its metastasis and recurrence. The general idea of cancer stem cells (CSCs) is primarily based on clinical and experimental observations, indicating the existence of a subpopulation of cells that can self-renew and differentiate. The EC stem cells, which can be isolated from normal pluripotent stem cells by applying similar biomarkers, may participate in promoting esophageal tumorigenesis through renewal and repair. In this review, major emphasis is given to CSC markers, altered CSC-specific pathways, and molecular targeting agents currently available to target CSCs of esophageal cancer. The roles of numerous markers (CD44, aldehyde dehydrogenase, CD133, and ATP-binding cassette subfamily G member 2) and developmental signaling pathways (Wnt/β-catenin, Notch, hedgehog, and Hippo) in isolating esophageal CSCs are discussed in detail. Targeting CSCs can be a logical strategy to treat EC, as these cells are responsible for carcinoma recurrence and chemoradiation resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.